ArticleFrontiers in veterinary science2025
Mechanistic investigation of Shuanghuanglian against infectious bronchitis in chickens: a network pharmacology and molecular dynamics study.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Network Pharmacology and Cross-Species Analysis Suggest a Potential Role of AKT1/HIF1A Axis in Shuanghuanglian for Pneumonia-Myocarditis Comorbidity.Veterinary sciences · 2026Article
- Herbal medicines against avian infectious bronchitis virus: shared host-directed and multi-stage antiviral pathways.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Infectious bronchitis (IB) poses a major challenge to global poultry production, causing substantial economic burdens and underscoring the necessity for novel therapeutic interventions given the limitations of current vaccines and conventional antiviral agents. The purpose of this study is to comprehensively explore the active components in Shuanghuanglian and their interaction with the key pathological targets of IBV (Infectious bronchitis virus) infection. By using advanced computational methods, this study aims not only to identify the therapeutic potential of active ingredients, but also to reveal their mechanism of action against IBV. Methods: Through integrative systems pharmacology approaches, we systematically investigated Shuanghuanglian and its phytochemical constituents against IB, employing multi-omics analysis, ensemble machine learning, and all-atom molecular dynamics (MD) simulations. Network pharmacology revealed 65 target genes associated with Shuanghuanglian's primary bioactive components (quercetin, kaempferol, wogonin, and luteolin), exhibiting high network centrality. Results: Using the TCMSP database, we found 65 target genes associated with key active components, such as quercetin and kaempferol, which exhibited strong connectivity in our network analysis. The GeneCards database also identified 40 common target genes shared by Shuanghuanglian and IB. Importantly, BCL2 and IL6 were recognized as key targets in the protein-protein interaction (PPI) network analysis, highlighting their roles in apoptosis and inflammation. Furthermore, analyses using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways revealed significant roles in regulating the cell cycle and inflammatory responses. Machine learning techniques identified BCL2 and IL6 as critical genes for therapeutic intervention, supported by molecular docking results that showed strong binding energies. Furthermore, molecular dynamics simulations confirm the stability of the complexes, underscoring the importance of these interactions for treatment efficacy. Conclusion: We used a variety of analytical methods, and finally identified the potential active ingredients of Shuanghuanglian as kaempferol, quercetin, wogonin, and luteolin. The active ingredients target BCL2 and IL6 and play a therapeutic role in avian infectious bronchitis by inhibiting apoptosis and reducing inflammatory response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.